[HLIND] YoY Annualized Quarter Result on 31-Dec-2014 [#2]

Stock
[HLIND] HONG LEONG INDUSTRIES BHD
Announcement Date
22-Jan-2015
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2015
Quarter
31-Dec-2014 [#2]
Profit Trend
QoQ- -13.03%
YoY- 7.17%
Quarter Report
Latest QR
Upcoming QR
HLIND's Result
HLIND's Financial Summary
View:
Show?
Annualized Quarter Result
31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 CAGR
Revenue 2,523,474 2,254,558 2,123,996 2,120,090 2,031,750 2,215,892 2,057,318 3.45%
PBT 470,098 364,840 326,154 324,382 227,956 187,030 207,678 14.57%
Tax -72,052 -52,118 -51,302 -108,426 -31,328 -37,242 -36,194 12.14%
NP 398,046 312,722 274,852 215,956 196,628 149,788 171,484 15.05%
-
NP to SH 329,608 266,866 238,150 167,578 156,364 105,156 138,788 15.49%
-
Tax Rate 15.33% 14.29% 15.73% 33.43% 13.74% 19.91% 17.43% -
Total Cost 2,125,428 1,941,836 1,849,144 1,904,134 1,835,122 2,066,104 1,885,834 2.01%
-
Net Worth 1,374,095 1,401,257 1,279,878 1,141,035 1,221,304 1,106,418 1,156,244 2.91%
Dividend
31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 CAGR
Div 92,844 92,594 80,185 74,013 61,682 61,638 67,832 5.36%
Div Payout % 28.17% 34.70% 33.67% 44.17% 39.45% 58.62% 48.88% -
Equity
31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 CAGR
Net Worth 1,374,095 1,401,257 1,279,878 1,141,035 1,221,304 1,106,418 1,156,244 2.91%
NOSH 327,905 327,905 308,404 308,387 308,410 308,194 308,331 1.03%
Ratio Analysis
31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 CAGR
NP Margin 15.77% 13.87% 12.94% 10.19% 9.68% 6.76% 8.34% -
ROE 23.99% 19.04% 18.61% 14.69% 12.80% 9.50% 12.00% -
Per Share
31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 CAGR
RPS 815.39 730.46 688.70 687.48 658.78 718.99 667.24 3.39%
EPS 106.42 86.52 77.22 54.34 50.70 34.12 45.02 15.40%
DPS 30.00 30.00 26.00 24.00 20.00 20.00 22.00 5.30%
NAPS 4.44 4.54 4.15 3.70 3.96 3.59 3.75 2.85%
Adjusted Per Share Value based on latest NOSH - 308,398
31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 CAGR
RPS 769.58 687.57 647.75 646.56 619.62 675.78 627.42 3.45%
EPS 100.52 81.39 72.63 51.11 47.69 32.07 42.33 15.48%
DPS 28.31 28.24 24.45 22.57 18.81 18.80 20.69 5.36%
NAPS 4.1906 4.2734 3.9032 3.4798 3.7246 3.3742 3.5262 2.91%
Price Multiplier on Financial Quarter End Date
31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 CAGR
Date 29/12/17 30/12/16 31/12/15 31/12/14 31/12/13 31/12/12 30/12/11 -
Price 9.69 9.40 5.93 4.49 4.84 4.62 4.00 -
P/RPS 1.19 1.29 0.86 0.65 0.73 0.64 0.60 12.07%
P/EPS 9.10 10.87 7.68 8.26 9.55 13.54 8.89 0.38%
EY 10.99 9.20 13.02 12.10 10.48 7.39 11.25 -0.38%
DY 3.10 3.19 4.38 5.35 4.13 4.33 5.50 -9.10%
P/NAPS 2.18 2.07 1.43 1.21 1.22 1.29 1.07 12.58%
Price Multiplier on Announcement Date
31/12/17 31/12/16 31/12/15 31/12/14 31/12/13 31/12/12 31/12/11 CAGR
Date 05/02/18 06/02/17 02/02/16 22/01/15 28/01/14 31/01/13 09/02/12 -
Price 9.50 9.76 5.62 4.35 5.31 4.40 4.28 -
P/RPS 1.17 1.34 0.82 0.63 0.81 0.61 0.64 10.56%
P/EPS 8.92 11.29 7.28 8.01 10.47 12.90 9.51 -1.06%
EY 11.21 8.86 13.74 12.49 9.55 7.75 10.52 1.06%
DY 3.16 3.07 4.63 5.52 3.77 4.55 5.14 -7.78%
P/NAPS 2.14 2.15 1.35 1.18 1.34 1.23 1.14 11.05%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment